Goldman Sachs
ABOS icon

Goldman Sachs’s Acumen Pharmaceuticals ABOS Stock Holding History

Goldman Sachs’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$488K Buy
206,683
+88,832
+75% +$227K ﹤0.01% 5611
2025
Q4 		$249K Sell
117,851
-29,297
-20% -$58.1K ﹤0.01% 5953
2025
Q3 		$252K Sell
147,148
-187,535
-56% -$260K ﹤0.01% 5849
2025
Q2 		$388K Buy
334,683
+138,476
+71% +$149K ﹤0.01% 5312
2025
Q1 		$216K Sell
196,207
-22,937
-10% -$32.8K ﹤0.01% 5606
2024
Q4 		$377K Buy
219,144
+73,283
+50% +$176K ﹤0.01% 5390
2024
Q3 		$362K Buy
145,861
+94,809
+186% +$257K ﹤0.01% 5216
2024
Q2 		$124K Sell
51,052
-266,852
-84% -$850K ﹤0.01% 5375
2024
Q1 		$1.29M Buy
317,904
+203,172
+177% +$766K ﹤0.01% 4174
2023
Q4 		$441K Buy
114,732
+57,433
+100% +$170K ﹤0.01% 4832
2023
Q3 		$238K Buy
57,299
+43,727
+322% +$270K ﹤0.01% 4980
2023
Q2 		$65.3K Sell
13,572
-28,730
-68% -$138K ﹤0.01% 5429
2023
Q1 		$172K Buy
42,302
+25,311
+149% +$132K ﹤0.01% 5347
2022
Q4 		$91.8K Sell
16,991
-5,626
-25% -$37.8K ﹤0.01% 5500
2022
Q3 		$227K Sell
22,617
-5,269
-19% -$30.2K ﹤0.01% 5425
2022
Q2 		$131K Sell
27,886
-306,309
-92% -$1.15M ﹤0.01% 5776
2022
Q1 		$1.31M Buy
334,195
+10,931
+3% +$59.5K ﹤0.01% 4608
2021
Q4 		$2.19M Buy
323,264
+259,629
+408% +$2.85M ﹤0.01% 4179
2021
Q3 		$946K Buy
+63,635
New +$1.06M ﹤0.01% 4788

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Goldman Sachs's ABOS Position: Q1 2026 in Review

Goldman Sachs increased its Acumen Pharmaceuticals (ABOS) stake by 75% in Q1 2026, buying an estimated $227K and bringing the position to 206,683 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #5611.

Goldman Sachs first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $2.19M in Q4 2021. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Goldman Sachs held 206,683 shares of Acumen Pharmaceuticals worth $488K as of Q1 2026.
  • Goldman Sachs bought 88,832 Acumen Pharmaceuticals shares in Q1 2026, an estimated $227K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5611 holding.
  • Goldman Sachs first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Goldman Sachs's Acumen Pharmaceuticals position peaked at $2.19M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.